



## Financial Tear Sheet

### Corporate Profile

Exicure, Inc. is a clinical stage biotechnology company developing a new class of immunomodulatory and gene regulating drugs against validated targets. Exicure's proprietary 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Exicure's lead programs address oncology, inflammatory diseases and genetic disorders.

### Primary IR Contact

MacDougall Biomedical  
Communications  
Karen Sharma

**Phone:** 781-235-3060

**E-mail:**

[ksharma@macbiocom.com](mailto:ksharma@macbiocom.com)

### Recent Headlines & Events

06/15/18 - 7:00 a.m.

[Exicure, Inc. to Present at the 2018 JMP Securities Life Sciences Conference on June 21st at 11:00 a.m. EDT](#)

There are currently no events scheduled.

06/14/18 - 7:00 a.m.

[Exicure to Present Data at the Cure Spinal Muscular Atrophy Annual Conference in Dallas](#)

06/04/18 - 7:00 a.m.

[Exicure, Inc. to Present at Jefferies 2018 Healthcare Conference on June 8th at 2:30 p.m. EDT](#)

### SEC Filings

Filing Date	Form
05/30/18	<a href="#"><u>8-K</u></a>
05/15/18	<a href="#"><u>10-Q</u></a>
05/15/18	<a href="#"><u>8-K</u></a>

04/30/18

4

Data provided by Nasdaq. Minimum 15 minutes delayed.